A5031591197- CAR-T cell therapy research
- Biomedical Ethics and Regulation
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Acute Myeloid Leukemia Research
- Immunotherapy and Immune Responses
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Galectins and Cancer Biology
- Immune cells in cancer
- Semiconductor materials and devices
- Biosimilars and Bioanalytical Methods
- Advancements in Semiconductor Devices and Circuit Design
- Toxin Mechanisms and Immunotoxins
- Cancer Immunotherapy and Biomarkers
- CRISPR and Genetic Engineering
- Advanced Glycation End Products research
- Nanowire Synthesis and Applications
- T-cell and B-cell Immunology
- Safe Handling of Antineoplastic Drugs
- Chronic Lymphocytic Leukemia Research
- Epilepsy research and treatment
- Synthesis of Organic Compounds
- Glycosylation and Glycoproteins Research
- Cytomegalovirus and herpesvirus research
City Of Hope National Medical Center
2020-2025
City of Hope
2020-2025
Occidental College
2018-2020
University of California, Los Angeles
1979-2014
Cedars-Sinai Medical Center
2008-2009
University of Massachusetts Chan Medical School
2008
Queen's University
2008
University Medical Center New Orleans
1998
Louisiana State University
1998
Aarhus University
1996
Background Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor that carries a 5-y survival rate of 5%. Attempts at eliciting clinically relevant anti-GBM immune response in patients have met with limited success, which due to privilege, evasion, and paucity dendritic cells (DCs) within central nervous system. Herein we uncovered novel pathway for activation an effective mediated by high-mobility-group box 1 (HMGB1), alarmin protein released from dying cells, acts as...
CD19-directed chimeric antigen receptor (CD19CAR) T-cell therapy has been successful in treating several B-cell lineage malignancies, including non-Hodgkin lymphoma (NHL). This modality not yet extended to NHL manifesting the central nervous system (CNS), primarily as a result of concerns for potential toxicity. CD19CAR T cells administered IV are detectable cerebrospinal fluid (CSF), suggesting that (CAR) can migrate from periphery into CNS, where they potentially mediate antilymphoma...
Abstract Lymphomas with central nervous system (CNS) involvement confer a worse prognosis than those without CNS involvement, and patients currently have limited treatment options. T cells genetically engineered CD19-targeted chimeric antigen receptors (CAR) are effective against B-cell malignancies show tremendous potential in the of systemic lymphoma. We aimed to leverage this strategy toward more therapy for lymphoma disease. NOD-scid IL2Rgammanull (NSG) mice and/or were treated CD19-CAR...
Dexamethasone (dex) is a glucocorticoid that mainstay for the treatment of inflammatory pathologies, including immunotherapy-associated toxicities, yet specific impact dex on activity CAR T cells not fully understood. We assessed whether given ex vivo or as an adjuvant in with impacted phenotype function cells. demonstrated cell expansion and were inhibited by dex. confirmed this observation using multiple constructs tumor models, suggesting general phenomenon. Moreover, we determined...
Post-transplantation cyclophosphamide (PTCy) is a safe and efficacious graft-versus-host-disease (GVHD) prophylaxis following hematopoietic cell transplantation (HCT) from haploidentical (haplo) donor. Cytokine release syndrome (CRS) common complication of this platform. Early fever post-haplo-HCT using bone marrow grafts associated with higher CD3+ dose CRS. However, the impact CD34+ on CRS peripheral blood stem (PBSC) unknown. Our goals were to evaluate incidence PBSC (PBSCT) identify...
Adoptive transfer of CD19-specific chimeric antigen receptor (CD19CAR) T cells can induce dramatic disease regression in patients with B cell malignancies. CD19CAR therapy may be limited by insufficient engraftment and persistence, resulting tumor relapse. We previously demonstrated a proof principle that cytomegalovirus (CMV)-specific isolated enriched prior to transduction produce CMV-CD19CAR cells, these expanded vivo through CMV vaccination, better control murine model. Here we developed...
The IL-3 alpha chain receptor (CD123) is a cell surface protein that widely expressed by various subtypes of acute leukemia, including myeloid leukemia (AML), lymphoblastic and blastic plasmacytoid dendritic neoplasm. Notably, CD123 preferentially overexpressed in stem cells (LSC) contrast to normal hematopoietic cells, this differential expression allows for the selective eradication LSC leukemic blasts through therapeutic targeting CD123, with less impact on cells. level AML correlates...
The resurgence of Group A
As the world of cellular therapy expands to include immune effector cell (IEC) products such as commercial chimeric antigen receptor (CAR) T cells, quality management (QM) professionals are faced with creating either new IEC stand-alone programs or expand existing hematopoietic transplantation (HCT) promote patient safety and be aligned quality, regulatory, accreditation requirements. The team at City Hope (COH) recently expanded HCT program and, in doing so, implemented regulatory...
Not available.